Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)
This study evaluates the effectiveness of robotic biopsies in providing information about hereditary or cancer specific genetic variants that may have a role in diagnosis of cancer and to develop genetic results and medical record databank for future studies.
Checked against the public recordLast updated Aug 26, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Mayo Clinic
- Interventions being studied
- Other: Non-Interventional Study
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subject age 18 years and older * Subject is scheduled/was scheduled for a bronchoscopy or surgical resection as part of standard of care * Subject with a moderate to high risk of lung cancer based on clinical demographic and radiologic information or with suspected metastatic disease * Ability to provide blood or saliva sample * Ability to provide archived tissue * Subject is able to understand and adhere to study requirements and able to provide informed consent Exclusion Criteria: * Individuals who have situations that would limit compliance with the study requirements * Institutionalized (i.e. federal medical prison) * Pregnant * Prior germline genetic testing with a 40+ multi-gene panel AND/OR prior somatic tissue (250+ gene) testing utilizing the tissue from the bronchoscopy or surgical resection
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo Clinic in RochesterRochester, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 26, 2026. Always confirm current availability with the study team.